Tyra Biosciences, Inc. (TYRA)
Nasdaq · Healthcare · Biotechnology
$20.93+2.45%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.4B
- 52-week range
- $12.98 – $40.65
- 52-week change
- +52.12%
- EPS (trailing)
- −$2.39
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Net income
- −$120M
- Diluted EPS
- −$2.01
- Free cash flow
- −$95.3M
From the company’s annual report on SEC EDGAR.
About Tyra Biosciences, Inc.
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
Headquarters: Carlsbad, United States · 87 employees · tyra.bio